J&J mulls the future of its med tech biz; Baxano raises $10M;

@FierceMedDev: Lombard Medical revives stateside IPO plans with a $55M debut. Article | Follow @FierceMedDev

@VarunSaxena2: BREAKING: Zimmer buying fellow orthopedics company Biomet for $13.35 billion. | Follow @VarunSaxena2

@EmilyWFierce: New genetic-bionic treatment for hearing loss could help improve pitch perception in those with cochlear implants. Article from Wired | Follow @EmilyWFierce

@MichaelGFierce: X-ray-activated nanoparticles release cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce

> After signing a deal to sell off its diagnostics business for $4.2 billion, Johnson & Johnson ($JNJ) is planning to sit down with investors next month and review the future of its med tech holdings. More

> Invacare ($IVC) is still working to get out from under an FDA consent decree blocking manufacturing at one of its U.S. facilities. News

> Baxano Surgical ($BAXS) raised $10 million in a private placement. Story

Biotech News

@FierceBiotech: An international biotech tackles CRISPR gene editing tech with $25M bankroll. More | Follow @FierceBiotech

@JohnCFierce: You gotta give $AZN credit. They keep spinning. Beefing up PhIII, which should have been Soriot's initial focus. More from the FT | Follow @JohnCFierce

@DamianFierce: $CELG opens down 5%. Perhaps a $710M deal didn't thrill investors who just watched R&D costs drag profits. | Follow @DamianFierce

@EmilyMFierce: Genetically engineered mosquitoes could be vital weapon against malaria. More from The Guardian | Follow @EmilyMFierce

> Hyperion bets up to $570M on diabetes biotech Andromeda. More

> AstraZeneca continues to chop back, spotlights immuno-oncology PhIII. Report

> J&J snags FDA OK for rare blood disorder drug siltuximab. Article

Pharma News

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Novartis, GSK team up in consumer JV to save big money, gain big scale. More | Follow @TracyStaton

@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Allergan poison pill presages a battle against Valeant's $47B takeover. Story | Follow @CarlyHFierce

> No big thrill from Novartis in Q1, just a 'solid' $14B in sales. News

> AstraZeneca CEO jumps into asset-sale fray to 'focus on what we do well.' Report

> Pfizer concedes Celebrex to Actavis, Teva after 2015 patent strike-down. Story

Pharma Manufacturing News

> FDA is now reporting recalls still awaiting classification. News

> China's Sinovac gets $9.6M grant to build vaccine plant. Article

> Report: Industry's regulatory-centric focus for manufacturing will no longer cut it. More

> Bristol-Myers extends manufacturing pact with Samsung. Story

> Wockhardt smacked by state regulator in India. Report

> Regulatory issues crush India's drug export growth. Item

Vaccines News

> Sinovac scores $9.6M Chinese grant for new hand, foot and mouth disease vaccine. Article

> Tetanus shot stored at higher temperatures as effective as cold chain-stored jab. More

> Immune discovery puts vaccine for H. pylori closer in sight. Story

> MERS vaccine to ease outbreak within 6 months, virologist says. Item

> Novartis bids farewell to vaccines with $7.1B sale to GSK. News

> U.K. health secretary asks Novartis CEO for Bexsero price cut. Report

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.